Partnerships

Helix, a leading population genomics company, provides patients and providers with powerful genetic insights that support proactive health planning. Helix’s solutions enhance healthcare delivery by advancing medical research, improving diagnosis and treatment, and supporting disease prevention. By making genomic data both accessible and actionable, this partnership enables the delivery of personalized, effective care at scale.

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. We are a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. Approximately 21,000 oncology professionals are involved in Group research. They include physicians, translational scientists, and associated research professionals from the member institutions, along with advocates.

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, ECOG-ACRIN is a vibrant component of the National Institutes of Health's National Cancer Institute (NCI) through its National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP). The NCI is our primary funder, through grants from these and other programs to our nonprofit ECOG-ACRIN Medical Research Foundation. We also receive financial support from private sector organizations through philanthropy and collaborations.

NRG Oncology seeks to improve the lives of patients with cancer by conducting practice-changing multi-institutional clinical and translational research with emphasis on sex-specific malignancies including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types.

Rutgers Cancer Institute together with RWJBarnabas Health is one of an elite group of comprehensive cancer centers in the U.S. designated by the National Cancer Institute and the only one in the state of New Jersey. This coveted designation gives Rutgers Cancer Institute the distinction of being among the best cancer research institutions in the nation.

The UPMC Stroke Institute's involvement with the NIH-funded StrokeNet research collaborative exemplifies its leadership in the realm of stroke research. Since StrokeNet's creation by the NIH in 2012, UPMC has been an integral participant, contributing to the network's mission of optimizing stroke prevention, treatment, and recovery strategies through comprehensive clinical trials. This collaboration leverages UPMC's extensive network of hospitals, enabling a wide-reaching infrastructure for conducting pivotal stroke research.